Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

There are some potential downsides though, including misuse by those who do not need to lose weight, some gastric side-effects and in limited cases, potentially pancreatitis and gall bladder disorders ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia.

Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia. By Ed Cara Published June 24, 2025 ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Neuroscientist Sabina Brennan encourages caregivers to live in the moment and notice the happy experiences they share with ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia. The active ingredient in ...

Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss ...